Differential activation of lipoprotein lipase from human post-heparin plasma, milk and adipose tissue by polypeptides of human serum Apolipoprotein C  by Ganesan, D. et al.
Volume 15, number 3 FEBS LETTERS June 197 1 
DIFFERENTIAL ACTIVATION OF LIPOPROTEIN LIPASE FROM HUMAN 
POST-HEPARIN PLASMA, MILK AND ADIPOSE TISSUE BY POLYPEPTIDES 
OF HUMAN SERUM APOLIPOPROTEIN C 
D. GANESAN, R.H. BRADFORD, P. ALAUPOVIC and W.J. McCONATHY 
Cardiovascular Section, Oklahoma Medical Research Foundation 
and the Departments of Biochemistry and Medicine, University of Oklahoma School of Medicine, 
Oklahoma City, Oklahoma 73104, USA 
Received 23 April 197 1 
1. Introduction 
Specific polypeptides of human serum apolipo- 
proteins have recently been found to activate tri- 
glyceride hydrolysis by LPL* from cow’s milk [l] 
and rat adipose tissue [2]. These investigators 
demonstrated a similar polypeptide specificity for 
activation of the enzyme from both sources. Poly- 
peptides containing glutamic acid or alanine as 
carboxyterminal amino acid, but not those con- 
taining valine, glutamine and threonine, served as 
activators. 
The present study was undertaken to evaluate 
the activation of purified LPL from human post- 
heparin plasma by immunochemically homogeneous 
polypeptides of human serum APO-A and APO-C 
and phosphatidylcholine. Inasmuch as the polypep- 
tide specificity of LPL from human post-heparin 
plasma was found to differ from that reported for 
LPL from cow’s milk [l] and rat adipose tissue 
[2] , additional studies were performed using LPL 
from human milk and adipose tissue as well as puri- 
fied LPL from dog and rat post-heparin plasma. 
Purified lipoprotein lipase from post-heparin 
plasma of normolipidemic subjects was activated 
* Abbreviations: 
LPL : lipoprotein lipase 
APO-A and ApoC: apolipoproteins A and C 
FFA: free fatty acids 
PC : phosphatidylcholine 
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to a greater extent by the R-valine polypeptide of 
APO-C than by its R-glutamic acid polypeptide. 
Neither the R-alanine polypeptide nor the R-threonine 
and R-glutamine polypeptides of apolipoprotein A 
served as an activator. This pattern of polypeptide 
specificity was similar to that observed for purified 
lipoprotein lipase from rat and dog post-heparin 
plasma, but differs from that for lipoprotein lipase 
from adipose tissue (human and rat) and milk 
(human and cow), suggesting the possibility that 
two distinct lipoprotein lipolytic activities are pre- 
sent in these tissues, 
2. Materials and methods 
2.1. Preparation of lipoprotein lipase 
Blood was obtained 30 min following the intra- 
venous administration of 10,000 units of heparin 
to subjects with normal serum lipid concentrations, 
who had fasted overnight. Plasma lipolytic activity, 
measured by in vitro assay [3], was normal in each 
subject. LPL was isolated and purified by a modi- 
fication [4] of the method of Fielding [S] . The 
purified enzyme eluted from calcium phosphate 
gel, designated LPkp, had a specific activity of 
2,000-2,500 units (one unit of enzyme releases 1 
E.tmole of free fatty acid per hr) per mg of protein, 
representing a purification of at least lO,OOO-fold. 
Results of immunochemical and electrophoretic 
analyses of LPkp have recently been reported [4]. 
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Additional purification of LPI_,-P using polyacryl- 
amide gel electrophoresis was performed to obtain 
an ap,olipoprotein-free lipase, designated LPL,, 
]41 . 
Human milk, obtained from a volunteer donor 
in the second month post-partum, was centrifuged 
at 3,250 g for 20 min at 5” and the cream layer 
discarded. After centrifugation was repeated once, 
the skimmed milk was lyophilized and the lyo- 
philized powder was dissolved in 0.05 M ammo- 
nium hydroxide-ammonium chloride buffer, pH 
8.5, 25 mg per ml [6]. Samples of subcutaneous 
adipose tissue were obtained from subjects at the 
time of surgery, and an acetone-ether powder 
prepared [7]. 
Studies of polypeptide specificity were also 
performed using purified LPL from rat and dog 
post-heparin plasma and LPL from rat epididymal 
fat. Blood was obtained 10 min (rats) or 20 mm 
(dogs) following the intravenous administration of 
100 units of heparin per kg body weight. Proce- 
dures similar to those described above were utilized 
for isolation and purification of LPL from plasma 
and for preparation of an acetone-ether powder 
of adipose tissue. 
2.2. Assay of lipolytic activity 
Lipolytic activity of enzyme preparations was 
measured using an assay mixture containing the 
following (per ml): 60 mg of bovine serum albumin 
(Armour, Fraction V), 25 pmoles of ammonium 
sulfate and 10 pmoles of 14C-triolein* (triolein 
[Analabs, Inc., North Haven, Corm.] containing 5 
I.tCi of glyceryl trioleate-l-14C [Amersham-Searle 
Corp., Arlington Heights, Ill.] per mmole, emulsified 
in 3 mg of gum arabic per pmole of triglyceride 
[3] ). Purified apolipoprotein polypeptides and/or 
egg phosphatidylcholine* (Analabs, Inc.) were added 
to the assay mixture as indicated. Incubations at 
pH 8.5 and 37’ were performed for 60 min and 
the production of 14C-oleic acid measured [8] . 
2.3. Preparation and characterization of apolipo- 
protein polypep tides 
APO-A and Apo-C and their polypeptides were 
* Thin-layer chromatographic analysis of these compounds 
demonstrated a single area with appropriate Rf value. 
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Fig. 1. Activation of purified LPLcP from human post- 
heparin plasma by ApoC and its R-Val and R-Glu poly- 
peptides isolated from human serum. Values for FFA 
release and polypeptide concentration are presented per 
ml of assay mixture. Each ml of assay mixture contained 
4 units of LPLCP and 20 pg of PC. Apparent K, values 
(presented as nmole of protein per ml of assay mixture): 
R-Val = 0.8, R-Clu = 2.8. 
isolated and purified from human serum high den- 
sity lipoproteins (d 1.063-1.210 g/ml) and very 
low density lipoproteins (d < 1.006 g/ml), using 
the procedure described previously [9]. Studies 
were performed using the following purified poly- 
peptides, which are designated by their carboxy 
terminal amino acid: R-glutamine, R-threonine, 
R-valine, R-alanine and R-glutamic acid. Criteria 
of homogeneity for individual purified polypep- 
tides included the demonstraton of a single pre- 
cipitin line when each polypeptide preparation 
was subjected to immunoelectrophoretic analysis, 
using specific antisera to APO-A, APO-C, R-Gln, 
R-Thr, R-Val or R-Ala. The amino acid compo- 
sition of APO-A [IO] and Apo-C [ 1 l] polypep- 
tides agreed with published results. 
3. Results and discussion 
LPkp from human post-heparin plasma hydro- 
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Table 1 
Activation of LPL from post-heparin plasma, adipose tissue 
and milk by ApoC and its R-Val, R-Glu and R-Ala poly- 
peptides. 
FFA Release (pmole/ml) 
~- 
ApoC R-Val R-C&I R-Ala 
- 
LPLCp* 
Human 1.14 1.68 1.08 0 
Rat 0.22 0.32 0.24 0 
Dog 0.42 0.62 0.33 0 
Adipose LPL** 
Human 0.08 0 0.15 0.05 
Rat 0.16 0 0.25 0.18 
Milk LPL** 
Human 0.20 0 0.42 0.20 
cow 0.18 0 0.40 0.18 
Values for FFA release are presented per ml of assay mix- 
ture. Each ml of assay mixture contained 20 pg of the poly- 
peptide indicated and 40 rg of PC. The R-Glu and R-Thre 
polypeptides were also evaluated and found to be inactive. 
* Each ml of assay mixture contained 4 units of enzyme. 
** Each ml of assay mixture contained 2.5 mg of protein 
from the acetone-ether extract of adipose tissue or 5 mg 
of skimmed milk protein. 
lyzed triolein in the presence but not in the absence 
of serum or phosphatidylcholine [4] . Activation 
of this purified enzyme was then evaluated using 
APO-A, APO-C and their polypeptides. APO-A and 
its R-Gln and R-Thr polypeptides, in concentrations 
up to 80 pg per ml, failed to activate LPkp. R-Val 
produced the greatest activation of LPLcp (fig. 1). 
APO-C and another of its polypeptides, R-Glu, but 
not R-Ala activated LPkp in the presence of phos- 
phatidylcholine. In the absence of phosphatidyl- 
choline, only R-Val served as an activator (less than 
10% of the value observed with phosphatidylcholine). 
The polypeptide specificity of apolipoprotein-free 
lipase, i.e. LPLP,, was similar to that observed for 
LPkp. Similar results were obtained using fifteen 
different preparations of LPLcp and five different 
preparations of each polypeptide. 
The polypeptide specificity of LPL from human 
milk and adipose tissue differed from human plasma 
LPL, inasmuch as the most potent activator (R-Val) 
of plasma LPL had no effect on milk and adipose 
tissue LPL (table 1). R-Glu activated LPL from human 
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Fig. 2. Activation of lipoprotein lipase from cow’s milk 
(upper panel) and rat adipose tissue (lower panel) by ApoC 
and its R-Glu and R-Ala polypeptides isolated from human 
serum. Values for FFA release and polypeptide concen- 
tration are presented per ml of assay mixture. Each ml of 
assay mixture contained either 5 mg of skimmed milk pro- 
tein or 2.5 mg of protein from the acetone-ether extract 
of adipose tissue, and, where indicated, 40 Mg of PC. Appa- 
rent K, values (presented as nmole of protein per ml of 
assay mixture): for milk lipase, R-Ala = 2.0, R-Glu = 3.1; 
for adipose tissue lipase, R-Ala = 1.1. 
milk and adipose tissue to a relatively greater extent 
than human plasma LPL. R-Ala activated human 
milk LPL, but had little effect on human plasma 
LPL. 
Purified LPL from dog and rat post-heparin plas- 
ma had a similar polypeptide specificity to that ob- 
served with human plasma LPL (table 1). A similar 
pattern of polypeptide specificity was also observed 
for LPL from human and rat adipose tissue (fig. 2) 
and for LPL from human and cow’s milk (fig. 2). The 
results for cow’s milk and rat adipose tissue obtained 
in the present study confirm those reported pre- 
viously [ 1,2] using LPL from these sources. 
The present study demonstrates two patterns of 
polypeptide specificity for LPL activation. One pattern 
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was observed in purified LPL from post-heparin 
plasma of human subjects, dogs and rats, and a 
second pattern was exhibited by LPL in adipose 
tissue from human subjects and rats, and in milk 
from human subjects and cows. These observa- 
tions suggest he possibility that at least two LPLs 
exist, one in post-heparin plasma and another in 
the other tissues studied. 
Preliminary results from studies undertaken 
recently in our laboratory indicate that LPLcp in 
post-heparin plasma from two subjects with type 
IV hyperlipoproteinemia exhibits a polypeptide 
specificity similar to that observed in controls. 
Nevertheless, the plasma LPLcp from two siblings 
with type 1 hyperlipoproteinemia was partially acti- 
vated by R-Glu and APO-C, but not by R-Val. This 
atypical pattern of polypeptide specificity provides 
additional evidence favoring the conclusion that 
the LPL present in type I hyperlipoproteinemia is 
abnormal, as has been suggested previously on the 
basis of results obtained from inhibitor and enzyme 
kinetics studies [3]. Alternatively, this observation 
might indicate that the LPL present in post-heparin 
plasma of other subjects is absent in type I hyper- 
lipoproteinemia. 
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